Galectin chair Uihlein receives 34,376,167 shares in debt-to-equity conversion

• Galectin chairman Richard E. Uihlein converted $105.8 million of convertible promissory notes into 34,376,167 common shares effective July 31, 2026.
• Uihlein is the company’s largest stockholder; the conversion eliminated all outstanding notes under five line-of-credit facilities.
• Common shares outstanding totaled 100,849,644 as of July 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-031058), on August 04, 2026, and is solely responsible for the information contained therein.